17 May 2016 - CADTH has received notice of a pending submission from Boehringer Ingelheim for Praxbind (idarucizumab) for the reversal of the anti-coagulant effects of dabigatran etexilate mesylate.

The submission is due on 30 May 2016.

For more details, go to: https://www.cadth.ca/idarucizumab-drug-plan-submission?utm_source=%2ALIVE%2A+CADTH%2FACMTS+Confirmed+Subscribers&utm_campaign=d271b30a94-Call-for-PI-Praxbind-5-17-2016&utm_medium=email&utm_term=0_2e3705996c-d271b30a94-262951505